This is an activity on the treatment and management of patients with lung cancer. The focus is on community-based medical oncology practices, but all clinicians caring for lung cancer patients are invited, including academic and research-based oncologists and allied healthcare practitioners.
The primary objective is to provide the target audience with the practical knowledge and best clinical practices to help them improve outcome in their lung cancer patients through a focus on personalized medicine with molecular and genomic testing and biomarkers, and an essential integration of the many new and emerging therapies into best practices for their lung cancer patients including immune therapy, new and novel targeted therapies, and novel uses of chemotherapy such as maintenance chemotherapy for squamous NSCLC. The target audience includes both academic and community-based lung cancer oncologists, pathologists, radiologists, surgeons, hematologists, fellows, oncology pharmacists, oncology nurses, Nurse Practitioners, physician assistants and other allied healthcare professionals. The focus is on community-based practices, but all clinicians are targeted, including academic and research-based oncologists and allied healthcare professionals.
On behalf of the world-class faculty of expert lung cancer medical oncologists, an Advanced Nurse Practitioner, and a Professor of Pharmacy, we are very pleased to invite you to attend. The activity will present practical information that is relevant to lung cancer practices, presented in case-based learning by lung cancer experts. It will provide the precise summarized information you need to be totally up-to-date on how to treat your lung cancer patients to improve their outcomes.
In 2017, lung cancer remains the leading cause of cancer deaths in the US, and also remains a significant unmet medical need, and, is expected to be a major clinical and scientific challenge for the foreseeable future, but with modest incremental advances. According to the American Cancer Society Facts and Figures there were an estimated 225,500 new cases, and 155,870 deaths from lung cancer this in 2016, almost identical to the prior year’s data. Survival rates for patients with lung cancer vary widely depending upon the stage of the lung malignancy when it is initially diagnosed. The five-year survival rate for Stage I NSCLC is approximately 50 percent. Perhaps more importantly, because most lung cancer are diagnosed at late stages of disease, especially Stages II and mostly IV, the five-year survival rate for Stage IV NSCLC is approximately two percent. Thus, it is clear that there is incredible opportunity for improving outcomes for patients with lung cancer. What is exciting and provides optimism are the increasing advances being made with immune therapy and new-generation targeted therapies, alone and in various combinations, including chemotherapy and existing targeted therapy, and especially for NSCLC patients with the EGFR mutation, the ALK-gene rearrangement, squamous NSCLC, and patients with rare driver mutations.
This activity is designed to meet the educational needs of and help close the quality clinical performance practice gaps of medical oncologists, radiation oncologists, surgical oncologists, pathologists, oncology pharmacists, oncology nurses/Nurse Practitioners and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer and Head & Neck Cancer, including physician assistants, fellows and other HCPs. Lung cancer and Head & Neck cancer are both treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation to these CME/CE activities for personalized therapies and best clinical practices.
Paul Bunn, Jr., MD (Co-Chair)
Hossein Borghaei, DO, MS
Walter J. Curran, Jr., MD
Marianne Davies, DNP, ACNP, AOCNP
Fred R. Hirsch, MD, PhD (Co-Chair)
Jim M. Koeller, MS
Ronald B. Natale, MD
Suresh Ramalingam, MD
Greg Riely, MD
Heather A. Wakelee, MD
Deborah A. Wong, MD, PhD
H. Jack West, MD
BioMedical Learning Institute
LEAD NURSE PLANNER
PLANNER & CME/CE REVIEWER
|CME/CE PEER REVIEWER
Danielle Shafer, MD
I have no real or apparent conflicts of interest to report.
This educational activity has been independently peer-reviewed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians' Desk Reference.
The Biomedical Learning Institute (BMLI) does not recommend the use of any agent outside of the FDA labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the BMLI. Please refer to the official FDA prescribing information for each product for discussion of approved indicated, contraindications, and warnings.
To receive CME/CE credit participation in the entire activity by viewing the activity and the completion of a brief evaluation form, participation in pre- and post-questions, and successfully passing a CME/CE test.
The Biomedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Biomedical Learning Institute designates this enduring activity for a maximum of 8.25 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
The Biomedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 8.25 hours (0.825 ceus)
Type of Activity: Knowledge
The Biomedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's COA.
The Biomedical Learning Institute designates this educational activity for 8.25 contact hours.
Accreditation by the American Nurses Credentialing Center's COA refers to recognition of educational activities and does not imply approval or endorsement of any product.
Participation at the entire activity, a 70% or better score on the post-test and completion of the evaluation form is required to receive CE contact hour credit.
Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 8.25 hours of Category 1 credit for attending this activity.
Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.
Sincere appreciation is extended to Bristol-Myers Squibb, Celgene, AstraZeneca, Takeda Oncology, Lilly, and Novartis for their generous support of this educational activity
Global Resource for Advancing Cancer Education (GRACE)
|Microsoft® Windows Vista®||Microsoft Internet Explorer 7, Firefox 2.0, AOL 9, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Microsoft Windows XP||Microsoft Internet Explorer 6.0 or later, Firefox 1.x, Firefox 2.x, Mozilla 1.x or later, Netscape 7.x or later, AOL 9, Opera 7.11 or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Microsoft Windows Server® 2003||Microsoft Internet Explorer 6.0 or later, Firefox 1.x, Firefox 2.x , Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Microsoft Windows 2000||Microsoft Internet Explorer 5.x, Firefox 1.x, Firefox 2.x, Mozilla 1.x, Netscape 7.x or later, AOL 9, Opera 7.11 or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Microsoft Windows Millennium Edition||Microsoft Internet Explorer 5.5, Firefox 1.x, Mozilla 1.x, Netscape 7.x or later, AOL 9, Opera 7.11 or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Microsoft Windows 98||Microsoft Internet Explorer 6.0 or later, Firefox 1.x, Mozilla 1.x, Netscape 7.x or later, Opera 7.11 or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Mac OS X v10.1 or later
|Firefox 1.x, Mozilla 1.x, Netscape 7.x or later, AOL for Mac OS X, Opera 6, Safari 1.x or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|
|Mac OS X v10.4.x or later
|Firefox 126.96.36.199 or later, Opera 6, Safari 2.x or later, Microsoft PowerPoint 2003 or later, Adobe Flash Player 8 or later, iTunes 7 or later|